Watch Mochida Pharmaceutical Co for free: we tell you when fair value or trend changes.

Mochida Pharmaceutical Co (MFY) fair value: what the stock is really worth

As of Oct 26, 2026: fair value (intrinsic value) of Mochida Pharmaceutical Co stock €14.92, price €18.59, upside -19.7%, quality 56 out of 100. Rating: overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? No
Good quality? Yes
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare · DE · Home Japan · ISIN JP3922800002

Broad data Oct 27, 2026

Mochida Pharmaceutical Co

MFY · F

Overvalued / MonitorQuality is not strong enough to offset the price risk.

Our calculation puts a fair price 20% below what the stock costs today.

Low debt

Ranks above peers (10/13)

Broad data

Quality 56/100

Expensive Growth (revenue 5y +2.6 %/yr in JPY)

Thin margins · 7.5% net margin (TTM)

2.4% dividend yield · Watch coverage

Fair value €14.92 · Overvalued (−19.7%)

Negative free cash flow

Narrow moat 37/100 · thin data

Price via web search⚠ Thinly traded

26 models, one by oneBear €13.41 to bull €16.19 Growth analysisrevenue history, year by year Quality 56/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Mochida Pharmaceutical Co for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 27, 2026.

How to read this chart

60‑month range €15.90 – €26.92 · fair‑value band €13.41 – €16.19 · the €18.59 price screens above the €14.92 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 27, 2026.

Follow Mochida Pharmaceutical Co in your weekly email

Every Wednesday you see whether Mochida Pharmaceutical Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Mochida Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals and healthcare products in Japan.

Show moreShow less

The company offers pharmaceuticals products for the treatment of cardiovascular, obstetrics, gynecology, dermatologists, psychiatry, and gastroenterological, including Realda and Collagen for the treatment of ulcerative colitis; Goofis and Movicol for the treatment of chronic constipation; interstitial pulmonary hypertension for the treatment of pulmonary arterial hypertension; Treprospermid, for pulmonary hypertension associated with ulcerative lung disease; Uris, for gout and hyperuricemia; and Clorox, for ulcerative colitis; Epadel for hyperlipidemia and obstructive arteriosclerosis; Treprost for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; Atelec, a calcium channel blocker antihypertensive drug; Heparin Na anticoagulants; and Onboard, ulcerative colitis and Crohn's disease treatment agents.

In addition, it develops medical devices, including dMD-002, which is used for the treatment of cavernous nerve injury; and dMD-003 for adhesion prevention material.

Further, the company engages in the development, production, distribution, sale, and marketing of skincare products, as well as academic research and marketing. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Shinjuku, Japan.

Stock analysis

Mochida Pharmaceutical Co (MFY) currently trades at €18.59, while our model-based Fair Value estimate is €14.92, 19.7% below the price, so the stock looks overvalued today.

Valuation

Bull case: the Multiples group reads highest at a median of €28.06 per share, and 7 of the 15 models we run sit above the €18.59 price.

Bear case: the Dividend Discount group reads lowest at €4.88, and 8 of the 15 models stay below the price. Data coverage for this calculation is high.

Scenario range: €13.41 (bear) to €16.19 (bull), the price of €18.59 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 56/100 (solid quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Mochida Pharmaceutical Co reported revenue of ¥117B in FY2026 versus ¥110B in FY2022, a compound +1.5%/yr. Reported net income was ¥7.9B in FY2026, compounding −7.0%/yr from FY2022.

Key figures

Market cap €659M Small · P/E ratio 15.0 · P/S ratio 1.01 · EPS (TTM) €1.24 · Dividend yield 2.4% · Net margin 6.8% · Return on equity 6.8% · Return on assets (EBIT) 5.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 37 out of 100 (low confidence).

What moves the price

The share trades about 13% below its 52-week high and 18% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −24% fair-value upside, at −20%, MFY screens cheaper than that median.

Fair Value models

Bear €13.41 Fair Value €14.92 Bull €16.19

Price €18.59 · Upside -19.7%

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then (€0.4521 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Best data coverage

Owner Earnings €6.97 €8.25 €10.16 78

Residual Income €17.13 €17.39 €18.33 76

EPV €13.41 €14.92 €16.19 74

All 15 models by family

DCF Models

Owner Earnings €6.97 €8.25 €10.16 78

Earnings-Based

Graham-Dodd €8.67 €16.41 €20.42 66

EPV €13.41 €14.92 €16.19 74

Dividend Discount

Gordon GGM €3.72 €4.88 €5.97 69

DDM Multi-Stage €3.72 €4.94 €6.25 67

Multiples

P/E Multiple €21.04 €28.06 €35.07 63

P/S Multiple €16.26 €21.68 €27.10 58

P/B Multiple €76.19 €101.58 €126.98 55

EV/EBIT €23.79 €30.75 €37.71 66

EV/EBITDA €25.15 €32.57 €39.98 67

EV/Revenue €17.81 €24.20 €30.59 54

Asset-Based

NCAV (Graham) €8.16 €12.36 €15.46 54

Economic Profit

Residual Income €17.13 €17.39 €18.33 76

ROIC Compounder €13.41 €14.92 €16.19 72

Growth Earnings

Growth-Adj P/E €15.01 €21.45 €27.88 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 56/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 41

How much profit the company makes from its sales and capital

Quality Growth 48

Are margins and returns getting better?

Cashflow 0

Do the profits arrive as real cash?

Financial strength 83

Debt, balance sheet and risk of trouble

Investment 86

Does it invest with discipline instead of growing at any price?

Low Volatility 85

How calm the share price moves, does not count

Momentum 50

Price trend of the last 3 to 12 months, does not count

Near the 52-week high 46

Distance to the 52-week high, does not count

New shares 87

Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 31/100

The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Revenue growth 1 year

+11.2%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+4.2%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+2.6%

Start year 2021 (pandemic). Over 10 years: +2.4% a year

Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+1.8%

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

’26

What shareholders gained per year (last 5 years), in JPY ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in JPY: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.

+0.6%

Earnings growth per share plus dividend.

Earnings per share, growth per year−1.8%

Dividend (yield on the price)2.4%

Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−0.1% vs 0.4%, steady

Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.12% → 9%

Pace: the 5-year rate starts in 2021 (pandemic)

MFY screens overvalued: fair value 20% below the price. Compare with Merck KGaA →

Compare Mochida Pharmaceutical Co with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 583 stocks

Beats the industry median on 10/13 measures

Overall it ranks above its industry peers.

Valuation

Quality Score 56 · Above median

Fair Value upside −19.7% · Below median

Profitability

Return on equity (12 months) 6.8% · Below median

Return on assets 4.3% · Above median

Net margin (12 months) 7.5% · Below median

Operating margin (12 months) 11.2% · Above median

Growth and dividend

Revenue growth (quarter YoY) 19.1% · Top 25%

Dividend yield (12 months) 2.4% · Above median

Balance sheet

Debt / equity 0.07× · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (12 months) 15.0× · Cheaper than median

P/B 0.81× · Cheapest 25%

P/S (12 months) 0.94× · Cheapest 25%

EV/EBITDA 6.8× · Cheapest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)7 · sector 19

FUTURE (revenue growth)96 · sector 26

PAST (return on equity)27 · sector 28

HEALTH (low debt)96 · sector 96

DIVIDEND (yield)49 · sector 33

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value	Compare
Zoetis Inc ZTS	$81.03	$110.26	+36%	vs MFY
Jiangsu Hengrui Pharmaceuticals Co 600276	¥47.38	¥52.12	+10%	vs MFY
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,745	₹1,920	+10%	vs MFY
Haleon plc HLN	$10.02	$8.57	−14%	vs MFY
Merck KGaA MRK	€143.30	€109.18	−24%	vs MFY
Galderma Group GALD	CHF 191.05	CHF 110.34	−42%	vs MFY
Takeda Pharmaceutical Company TAK	$20.24	$11.42	−44%	vs MFY
Teva Pharmaceutical Industries Limited TEVA	$39.41	$20.82	−47%	vs MFY
Sandoz Group SDZ	CHF 78.48	CHF 40.20	−49%	vs MFY
Divi's Laboratories Limited DIVISLAB	₹9,190	₹1,871	−80%	vs MFY

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator P/E Ratio Calculator PEG Ratio Calculator Graham Number Peter Lynch Formula DDM Calculator Intrinsic Value Intrinsic vs Extrinsic Value P/E Ratio by Sector

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Mochida Pharmaceutical Co · Fair Value
€14.92 −20%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/MFY" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Mochida Pharmaceutical Co · Fair Value</span><br><b style="font-size:20px">€14.92</b> <span style="color:var(--red);font-weight:700;font-size:14px">−20%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Mochida Pharmaceutical Co Fair Value". https://www.fairvalue-calculator.com/stock/MFY

Frequently asked questions

Is Mochida Pharmaceutical Co (MFY) overvalued or undervalued?

As of Oct 27, 2026, our model estimates a fair value of €14.92 versus a price of €18.59, about −20% upside (overvalued).

What is the fair value of MFY?

Our model-based fair value for Mochida Pharmaceutical Co is €14.92 (as of Oct 27, 2026), built from audited fundamentals. The current price: €18.59.

What is the quality score of MFY?

Mochida Pharmaceutical Co has a Quality Score of 56/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Mochida Pharmaceutical Co (MFY)?

Our model-based price target is the fair value of €14.92 (as of Oct 27, 2026) from 15 valuation models. Cautious scenario €13.41, optimistic scenario €16.19. It is a calculation from audited fundamentals, not an analyst target.

What is the Mochida Pharmaceutical Co stock forecast for 2026?

Our models put fair value at €14.92, about −20% upside versus a price of €18.59 (overvalued). Cautious scenario €13.41, optimistic scenario €16.19. The calculation is refreshed regularly with new filings.

What is the revenue of Mochida Pharmaceutical Co (MFY)?

Mochida Pharmaceutical Co reported trailing-twelve-month revenue of about ¥122B (latest available figure, as of Oct 27, 2026).

Does Mochida Pharmaceutical Co pay a dividend?

Mochida Pharmaceutical Co currently shows a dividend yield of 2.44% relative to its recent price (as of Oct 27, 2026).

What is the intrinsic value of Mochida Pharmaceutical Co (MFY)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Mochida Pharmaceutical Co it is €14.92 per share (as of Oct 27, 2026), against a price of €18.59. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).

Is Mochida Pharmaceutical Co stock overvalued or undervalued in 2026?

As of Oct 27, 2026, MFY trades above its calculated fair value: price €18.59, fair value €14.92, a gap of about −20% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of MFY?

No. The price is what the market pays today (€18.59); the fair value is what the company's own numbers justify (€14.92). For Mochida Pharmaceutical Co the two are €3.67 per share apart. That gap is exactly why we show both numbers side by side.

How much is Mochida Pharmaceutical Co worth?

The market values Mochida Pharmaceutical Co at about €659M (market capitalisation, as of Oct 27, 2026). Per share that is €18.59; our models calculate a fair value of €14.92 per share.

What do the bullish and bearish scenarios say about MFY?

Our models span a range for Mochida Pharmaceutical Co: cautious scenario €13.41, base €14.92, optimistic €16.19 per share (as of Oct 27, 2026, price €18.59). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of MFY?

Mochida Pharmaceutical Co trades at a price-to-earnings ratio of 15.0 (as of Oct 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €14.92 is built from several models across several years. Other multiples: P/B 0.8, P/S 0.9, EV/EBITDA 6.8.

How solid is the balance sheet of Mochida Pharmaceutical Co (MFY)?

Balance-sheet figures for Mochida Pharmaceutical Co (as of Oct 27, 2026): return on equity 6.8%, debt of 0.07 per unit of equity. They feed the Quality Score of 56/100, which measures business quality independently of the share price.

How far is MFY from its 52-week high?

Mochida Pharmaceutical Co trades at €18.59, about 13% below its 52-week high of €21.26 and 18% above the low of €15.80 (as of Oct 23, 2026). Distance from the high says nothing about value: that is what the fair value of €14.92 is for.

Which stocks are comparable to Mochida Pharmaceutical Co?

From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Mochida Pharmaceutical Co stock attractive at the current price?

The data as of Oct 27, 2026: price €18.59, calculated fair value €14.92 (−20%), Quality Score 56/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of MFY calculated?

We run Mochida Pharmaceutical Co through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €14.92, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 12.7 % above its aggregate fair value. Mochida Pharmaceutical Co itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Mochida Pharmaceutical Co (MFY)?

The closing price on Oct 26, 2026 was €18.59. Our model-based fair value is €14.92, about −20% upside (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Mochida Pharmaceutical Co right now?

The price sits above even our optimistic bull case (€16.19). The favourable scenario is already priced in. Solid but not exceptional quality (56/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Mochida Pharmaceutical Co

How large is the market capitalisation of Mochida Pharmaceutical Co (MFY)?

The market capitalisation of Mochida Pharmaceutical Co is €659M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Mochida Pharmaceutical Co (MFY)?

The price-to-sales ratio of Mochida Pharmaceutical Co is 1.01 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Mochida Pharmaceutical Co (MFY)?

Earnings per share at Mochida Pharmaceutical Co are €1.24 (price ÷ EPS = P/E 15.0). Earnings per share over the last twelve months: total profit spread across every single share.

What is the dividend yield of Mochida Pharmaceutical Co (MFY)?

The dividend yield of Mochida Pharmaceutical Co is 2.4% (payout 36.6%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of Mochida Pharmaceutical Co (MFY)?

The net margin of Mochida Pharmaceutical Co is 6.8% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Mochida Pharmaceutical Co (MFY)?

The return on equity (ROE) of Mochida Pharmaceutical Co is 6.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Mochida Pharmaceutical Co (MFY)?

On an EBIT basis the return on assets of Mochida Pharmaceutical Co is 5.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Mochida Pharmaceutical Co (MFY)?

The operating margin of Mochida Pharmaceutical Co is 11.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Mochida Pharmaceutical Co (MFY)?

Revenue at Mochida Pharmaceutical Co is growing +19.1% versus a year earlier (3y avg +4.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Mochida Pharmaceutical Co (MFY)?

Earnings per share at Mochida Pharmaceutical Co are growing +68.0% versus a year earlier. How much earnings per share grew versus a year earlier.

How much free cash flow does Mochida Pharmaceutical Co (MFY) generate?

The free cash flow of Mochida Pharmaceutical Co is −¥10.0B (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

Free · no account needed

Watch Mochida Pharmaceutical Co in the live analysis

One click puts Mochida Pharmaceutical Co on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.